Hayleigh Culliton

Dec 9, 2024 | healtheconomics.com | Michael Grabner |Carelon Research |Hayleigh Culliton

Written by: Michael Grabner, PhD, Principal Scientist, Carelon ResearchInterest in the use of real-world data (RWD) and real-world evidence (RWE) for regulatory and insurance coverage decision-making in the US has increased substantially over the past decade.1-3 The US Food and Drug Administration’s (FDA) RWE framework has catalyzed the generation and integration of RWE for pharmaceuticals and medical devices.

Nov 25, 2024 | healtheconomics.com | Hayleigh Culliton

HealthEconomics.com recently sat down for a conversation with Dr. David W. Miller, Chairman and CEO of Genesis Research Group, about his vision for the business, the changing face of research, and their unique value proposition for the life science industry. The life science industry is a complex and dynamic marketplace where life sciences companies are constantly having to adapt their research needs to changing circumstances.

Jun 17, 2024 | healtheconomics.com | Michael Broder |Hayleigh Culliton

By: Michael S. Broder, MD, MSHS, President – PHAR“What’s in a name? That which we call a rose/ By any other name would smell as sweet.”–William Shakespeare, Romeo and JulietIf you attended the ISPOR International conference in May, you couldn’t have missed that the most common phrase used in a session title was “artificial intelligence.” No surprise there, given how thoroughly AI had dominated the headlines for the last 6 months.

Jan 23, 2024 | healtheconomics.com | Hayleigh Culliton

Real world research has produced recent newsworthy findings on topics as diverse as COVID, mental health, cancer, and dementia. But much of the published RWE, even among studies that end up in headlines, doesn’t include crucial information readers need to know in order to trust the results—by that I mean information on the validity of the link between the coded information that forms the basis of the study and the actual health states of interest.

Jul 5, 2023 | blogsite.healtheconomics.com | Hayleigh Culliton

Supplier Spotlight® highlights the unique skills and services offered by organizations that are part of our CONNECTED COMMUNITY™. Recently, we spoke with LexisNexis Risk Solutions which supports the biopharma industry by offering scientific data solutions and consultancy centered around regulatory expertise. Check out the interview below and visit LexisNexis Risk Solutions. What is your company’s mission?